Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658396 | 0.86 | EPHX2 (0.56) | EPHX2KDM4ESMN1; SMN2L3MBTL1KCNH2 | |
| SCHEMBL13873113 | 0.84 | EPHX2 (0.57) | EPHX2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL29566603 | 0.84 | GPR119 (0.61) | EPHX2KDM4ESMN1; SMN2GPR119 | |
| SCHEMBL1088570 | 0.84 | GPR119 (0.61) | EPHX2KDM4ESMN1; SMN2GPR119 | |
| SCHEMBL27648403 | 0.83 | KDM4E (0.59) | EPHX2KDM4ESMN1; SMN2L3MBTL1KCNH2 | |
| SCHEMBL19658750 | 0.82 | EPHX2 (0.54) | EPHX2KDM4ESMN1; SMN2L3MBTL1KCNH2 | |
| SCHEMBL17886759 | 0.81 | ABL1 (0.60) | SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL18973366 | 0.79 | GPR119 (0.56) | EPHX2KDM4EGPR119 | |
| SCHEMBL17888371 | 0.79 | SLC6A7 (0.55) | EPHX2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL17886847 | 0.79 | KDM4E (0.47) | EPHX2KDM4ESMN1; SMN2L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | EPHX2 2560/4885KDM4E 320/4885SMN1; SMN2 1221/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | EPHX2 2560/4885KDM4E 320/4885SMN1; SMN2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.